Didier Autran

264 Rue Saint Pierre
Marseille, 13005, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review.

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review.

Journal: Discover oncology

Published: November 24, 2025

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Journal: Journal of neuro-oncology

Published: August 26, 2025

Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma.

Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma.

Journal: Anticancer research

Published: July 31, 2024

Radio-chemotherapy feasibility for biopsy-only unresectable IDH wild-type glioblastomas (BO-GBM).

Radio-chemotherapy feasibility for biopsy-only unresectable IDH wild-type glioblastomas (BO-GBM).

Journal: Neuro-oncology practice

Published: November 27, 2023

Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.

Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.

Journal: Journal of neuro-oncology

Published: November 15, 2021

Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.

Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.

Journal: Journal of cancer survivorship : research and practice

Published: November 12, 2021

Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.

Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.

Journal: Neuro-oncology

Published: February 08, 2021

TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study.

TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study.

Journal: The oncologist

Published: January 11, 2021

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 03, 2019

Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.

Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.

Journal: Anticancer research

Published: December 05, 2018

Neuro-oncological patients admitted in intensive-care unit: predictive factors and functional outcome.

Neuro-oncological patients admitted in intensive-care unit: predictive factors and functional outcome.

Journal: Journal of neuro-oncology

Published: September 12, 2015

Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen.

Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen.

Journal: Anticancer research

Published: May 13, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026